360 NEWS360 NEWS
Home / Business

Danes Are Crooning Over Novo Despite Drugmaker’s Share Slump

It’s been a painful couple of years for Denmark’s nearly 700,000-strong army of retail investors in Novo Nordisk A/S as the weight-loss drugmaker has lost market share to US rival Eli Lilly & Co.

Published
Original News Source Bloomberg — Business
Content & Media Rights Sara Sjolin / Bloomberg — Business
Editorial Publisher 360 NEWS (Independent Media)
It’s been a painful couple of years for Denmark’s nearly 700,000-strong army of retail investors in Novo Nordisk A/S as the weight-loss drugmaker has lost market share to US rival Eli Lilly & Co.

Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].